2016
BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer
Bansal N, Bartucci M, Yusuff S, Davis S, Flaherty K, Huselid E, Patrizii M, Jones D, Cao L, Sydorenko N, Moon Y, Zhong H, Medina D, Kerrigan J, Stein M, Kim I, Davis T, DiPaola R, Bertino J, Sabaawy H. BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer. Clinical Cancer Research 2016, 22: 6176-6191. PMID: 27307599, PMCID: PMC5159329, DOI: 10.1158/1078-0432.ccr-15-3107.Peer-Reviewed Original ResearchConceptsTumor-initiating cellsProstate tumor-initiating cellsBmi-1Androgen receptor-directed therapyIntrinsic therapy resistanceReceptor-directed therapyProstate cancer managementProstate cancer treatmentMore effective therapiesBmi-1 expressionProstate cancer cellsStem cell-like traitsSelf-renewing tumor-initiating cellsCell-like traitsPatient-derived cellsEffective therapyTumor relapseCancer managementXenograft modelTherapy resistancePharmacologic inhibitionBmi-1 functionTherapyNormal tissuesCancer treatment
2013
Therapeutic Role of Bmi-1 Inhibitors in Eliminating Prostate Tumor Stem Cells
Kim I, Bertino J, Sabaawy H. Therapeutic Role of Bmi-1 Inhibitors in Eliminating Prostate Tumor Stem Cells. 2013 DOI: 10.21236/ada598365.Peer-Reviewed Original ResearchProstate tumor-initiating cellsTumor-initiating cellsBmi-1Stem cellsTreatment of zebrafishCancer cell senescenceMouse xenograftsZebrafish xenograft modelCell cycle arrestG1 cell cycle arrestCellular senescenceTranslational inhibitorBmi-1 expressionTumor stem cellsCell senescenceCycle arrestCurrent therapiesTherapeutic roleProstate cancerInvasion abilityTherapeutic strategiesXenograft modelCD44hi cellsTumor growthMetastatic potential